In vivo toxicity evaluation of gold-dendrimer composite nanodevices with different surface charges

Nanotoxicology

Volumn 7, Issue 4, 2013, Pages 441-451

  Kasturirangan, Venugopalan ^a   Nair, Bindu M ^a   Kariapper, Muhammed T S ^a   Lesniak, Wojciech G ^a   Tan, Wei ^a   Bizimungu, Remy ^a   Kanter, Peter ^a   Toth, Karoly ^a   Buitrago, Sandra ^a   Rustum, Youcef M ^a   Hutson, Alan ^a   Balogh, Lajos P ^a   Khan, Mohamed K ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Biosafety; Composite nanodevice; in vivo toxicity; Nanoparticle; PAMAM dendrimer

Indexed keywords

ALBUMIN; GOLD; NANOCOMPOSITE; POLYAMIDOAMINE; PROTEIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; AUTOPSY; BIOSAFETY; BLOOD CHEMISTRY; BODY WEIGHT; CLINICAL CHEMISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; DEHYDRATION; EVALUATION; HISTOPATHOLOGY; HOMEOSTASIS; IN VIVO STUDY; LETHARGY; LIVER NECROSIS; LYMPHOID TISSUE; MALE; MOTOR DYSFUNCTION; MOUSE; NANODEVICE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYPLOIDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLEX; SURFACE CHARGE; TOUCH; TOXICITY; WEIGHT CHANGE; WEIGHT GAIN; ZETA POTENTIAL;

ANIMALS; BODY WEIGHT; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMISTRY; GOLD; KIDNEY; LIVER; LUNG; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED C57BL; PANCREAS; SPLEEN;

EID: 84877270919     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2012.668570     Document Type: Article

References (47)

1. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, et al. 2011. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 6: e24374.
2. Balogh LP, Khan MK. 2007. Dendrimer nanocomposites for cancer therapy. Boca Raton, FL: CRC Press-Taylor & Francis Group.
3. Balogh L, Nigavekar SS, Nair BM, Lesniak W, Zhang C, Sung LY, et al. 2007. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine 3: 281-296. (Pubitemid 350199641)
4. Balogh L, Valluzzi R, Laverdure KS, Gido SP, Hagnauer GL, Tomalia DA. 1999. Formation of silver and gold dendrimer nanocomposites. J Nanopart Res 1: 353-368. (Pubitemid 129636196)
5. Bar-Ilan O, Albrecht RM, Fako VE, Furgeson DY. 2009. Toxicity assessments of multisized gold and silver nanoparticles in zebrafish embryos. Small 5: 1897-1910.
6. Bielawski K, Bielawska A, Muszynska A, Poplawska B, Czarnomysy R. 2011. Cytotoxic activity of G3 PAMAM-NH(2) dendrimer-chlorambucil conjugate in human breast cancer cells. Environ Toxicol Pharmacol 32: 364-372.
7. Bielinska A, Eichman JD, Lee I, Baker JR Jr, Balogh L. 2002. Imaging {Au0-PAMAM} gold-dendrimer nanocomposites in cells. J Nanopart Res 4: 395-403.
8. Bouwmeester H, Lynch I, Marvin HJ, Dawon KA, Berges M, Braguer D, et al. 2011. Minimal analytical characterization of. engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology 5: 1-11.
9. Daftarian P, Kaifer AE, Li W, Blomberg BB, Frasca D, Roth F, et al. 2011. Peptide-conjugated PAMAM dendrimer as a universal platform for antigen presenting cell targeting and effective DNA-based vaccinations. Cancer Res 71: 7452-62.
10. Degeorge JJ, Ahn CH, Andrews PA, Brower ME, Giorgio DW, Goheer MA, et al. 1998. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41: 173-185. (Pubitemid 28094040)
11. Duncan R, Izzo L. 2005. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57: 2215-2237. (Pubitemid 41759394)
12. Gaspar R, Duncan R. 2009. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 61: 1220-1231.
13. Greish K, Thiagarajan G, Herd H, Price R, Bauer H, Hubbard D, et al. 2011. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology; Epub ahead of print.
14. Gulumian M, Vallyathan V. 2010. Nanoparticles and potential human health implications: past and future directions. Preface. J Toxicol Environ Health A 73: 339-340.
15. Hagens WI, Oomen AG, De Jong WH, Cassee FRA, Sips AJ. 2007. What do we need to know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol 49: 217-219.
16. Hong S, Leroueil PR, Janus EK, Peters JL, Kober MM, Islam MT, et al. 2006. Interaction of polycationic polymers with supported lipid bilayers and cells: Nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem 17: 728-734. (Pubitemid 43794383)
17. Jevprasesphant R, Penny J, Jalal R, Attwood D, Mckeown NB, D'emanuele A. 2003. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm 252: 263-266. (Pubitemid 36126635)
18. Khan MK, Nigavekar SS, Minc LD, Kariapper MST, Nair BM, Lesniak WG, et al. 2005. In vivo biodistribution of dendrimers and dendrimer nanocomposites-Implications for cancer imaging and therapy. Technol Cancer Res Treat 4: 603-613. (Pubitemid 43083344)
19. King Heiden TC, Dengler E, Kao WJ, Heideman W, Peterson RE. 2007. Developmental toxicity of low generation PAMAM dendrimers in zebrafish. Toxicol Appl Pharmacol 225: 70-79. (Pubitemid 350016213)
20. Kolhatkar RB, Kitchens KM, Swaan PW, Ghandehari H. 2007. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem 18: 2054-2060. (Pubitemid 350220008)
21. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. 2005. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65: 5317-5324. (Pubitemid 40827344)
22. Lee JH, Cha KE, Kim MS, Hong HW, Chung DJ, Ryu G, et al. 2009. Nanosized polyamidoamine (PAMAM) dendrimer-induced apoptosis mediated by mitochondrial dysfunction. Toxicol Lett 190: 202-207.
23. Lesniak WG, Kariapper MST, Nair BM, Tan W, Hutson A, Balogh LP, et al. 2007. Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting avb3 integrins. Bioconjug Chem 18: 1148-1154. (Pubitemid 47122636)
24. Li C, Liu H, Sun Y, Wang H, Guo F, Rao S, et al. 2009. PAMAM dendrimer nanoparticles promote acute lung injury by inducing autophagic cell death through Akt-TSC2-mTOR signaling pathway. J Mol Cell Biol 1: 37-45.
25. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. 2000. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 65: 133-148. (Pubitemid 30122922)
26. Mcneil SE. 2005. Nanotechnology for the biologist. J Leukoc Biol 78: 585-594. (Pubitemid 41292080)
27. Miyano T, Wijagkanalan W, Kawakami S, Yamashita F, Hashida M. 2010. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol Pharm 7: 1318-1327.
28. Myc A, Majoros IJ, Thomas TP, Baker JR Jr. 2007. Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules 8: 13-18. (Pubitemid 46140467)
29. Nair BM, Kariapper MST, Lesniak WG, Tan W, Hutson A, Khan MK, et al. 2009. Toxicity evaluation of gold-dendrimer composite nanodevices in vitro: difference found between tumour and proliferating endothelial cells. Nanotoxicology 3: 1743-5404.
30. Nigavekar SS, Sung LY, Llanes M, El-Jawahri A, Lawrence TS, Becker CW, et al. 2004. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res 21: 476-483.
31. Oberdorster G, Stone V, Donaldson K. 2007. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1: 2-25. (Pubitemid 46570244)
32. Research L. 2007. The Nanotech Report. 5th ed. New York: Lux Research.
33. Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R, et al. 2002. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 5: 104-114. (Pubitemid 34144826)
34. Riveragil P, Oberdorster G, Elder A, Puntes V, Parak WJ. 2010. Correlating physico-chemical with toxicological properties of nanoparticles: the present and the future. ACS Nano 4: 5527-5531.
35. Roberts JC, Bhalgat MK, Zera RT. 1996. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 30: 53-65.
36. Sanhai WR, Sakamoto JH, Canady R, Ferrari M. 2008. Seven Challenges for Nanomedicine. Nat Nanotechnol 3: 242-244. (Pubitemid 351668048)
37. Seib FP, Jones AT, Duncan R. 2007. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release 117: 291-300. (Pubitemid 46216575)
38. Shi X, Wang S, Meshinchi S, Van Antwerp ME, Bi X, Lee I, et al. 2007. Dendrimer-entrapped gold nanoparticles as a platform for cancercell targeting and imaging. Small 3: 1245-1252. (Pubitemid 47114383)
39. Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. 2006. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 17: 1109-1115. (Pubitemid 44455317)
40. Sonavane G, Tomoda K, Makino K. 2008. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 66: 274-280.
41. Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A & et al. 2005. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 48: 3729-3735. (Pubitemid 40776848)
42. Van Zwieter MJ, Hollander CF. 1985. Monographs on the Pathology of Laboratory Animals : Digestive Systems. Berlin: Springer-Verlag.
43. Wang J Xia J. 2011. Preferential binding of a novel polyhistidine peptide dendrimer ligand on quantum dots probed by capillary electrophoresis. Anal Chem 83: 6323-6329.
44. Xu R, Wang Y, Wang X, Jeong EK, Parker DL, Lu ZR. 2007. In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med 232: 1081-1089. (Pubitemid 47358191)
45. Zhao J, Castranova V. 2011. Toxicology of nanomaterials used in nanomedicine. J Toxicol Environ Health B Crit Rev 14: 593-632.
46. Zhu W, Okollie B, Bhujwalla ZM, Artemov D. 2008a. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 59: 679-685. (Pubitemid 351501930)
47. Zhu X, Zhu L, Duan Z, Qi R, Li Y, Lang Y. 2008b. Comparative toxicity of several metal oxide nanoparticle aqueous suspensions to Zebrafish (Danio rerio) early developmental stage. J Environ Sci Health A Tox Hazard Subst Environ Eng 43: 278-284.